Physicians' Academy for Cardiovascular Education

Hypertension

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD

New recommendations of the ESC/ESH Guidelines on the management of hypertension

3' education - Feb. 11, 2019 - Prof. Bryan Williams - London, UK

Get involved in May Measurement Month to increase awareness of elevated blood pressure

3' education - Feb. 6, 2019 - Prof. Neil Poulter - London, UK

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The future of renal denervation in the treatment of hypertension

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany

Pharmacist intervention in black barbershop beats usual care at lowering BP

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA

New ACC/AHA hypertension guidelines empasize risk assessment

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

Good BP measurement depends more on appropriate technique than on absence of staff

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Karen Johnson - Memphis, TN, USA

Target for BP lowering differs between Europe and USA

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

New ACC/AHA Hypertension Guidelines: stress on accuracy BP measurement method and lifestyle changes ánd a new target

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Paul Whelton, MD (Tulane University, New Orleans, LA, USA

BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study

3' education - Aug. 29, 2017 - Dr. Wilko Spiering - UMCU

Take home messages of the ESC congress for better hypertension treatment

3' education - Aug. 29, 2017 - Dr. Clyde Jancy - Northwestern University, Feinberg University, Chicago, IL, VS

Well-conducted trial confirms principle that renal denervation can lower blood pressure

3' education - Aug. 29, 2017

NSAID ibuprofen increases blood pressure significantly more than other selective COX2 inhibitors

3' education - Aug. 28, 2017

E-counselling improves adherence in hypertensives

3' education - Mar. 21, 2017 - Dr. Rob Nolan, Toronto, ONT, Canada

Get involved in May Measurement Month!

3' education - Jan. 22, 2017 - London, United Kingdom - Prof. Neil R Poulter, MD (London, UK) - ISH President

How low to go with blood pressure: J-curve or not?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Deepak L.Bhatt, MD, MPH (Boston, MA, USA)

To SPRINT or not to SPRINT to a lower blood pressure target?

10' education - Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)
##SCROLLER_ITEMS_FULL_TITLE##

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

10' education - May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
##SCROLLER_ITEMS_FULL_TITLE##

HOPE-3: Statin therapy works in everybody with intermediate-risk

3' education - Apr. 8, 2016 - Salim Yusuf MD, McMaster University, Hamilton, Ontario
##SCROLLER_ITEMS_FULL_TITLE##

PARAMETER: heart failure agent to treat hypertension

3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
##SCROLLER_ITEMS_FULL_TITLE##

PARAMETER: heart failure agent to treat hypertension

3' education - Sep. 1, 2015 - ESC - Londen 2015 - Bryan Williams
##SCROLLER_ITEMS_FULL_TITLE##

PATHWAY-2: which agent can best treat therapy resistant hypertension?

3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
##SCROLLER_ITEMS_FULL_TITLE##

PARADIGM-HF: Rationale, results & implications

3' education - Dec. 11, 2014 - Chicago, Il, USA VBWG - John J McMurray
##SCROLLER_ITEMS_FULL_TITLE##

CV Risk management in Russia

3' education - Dec. 3, 2014 - Moscow - Prof Andrey Susekov
##SCROLLER_ITEMS_FULL_TITLE##

Innovating hypertension: targeting the underlying disease process

3' education - Sep. 8, 2014 - Barcelona - Prof Bryan Williams

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD
Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the. mangement of CKD with resistant hypertension.

Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the mangement of CKD with resistant hypertension.

Use of patiromer results in more patients remaining on spironolactone in resistant hypertension and CKD, with and without HF

News - May 25, 2019
Addition of patiromer to spironolactone showed that a higher percentage of patients remained on spironolactone vs. those on placebo and spironolactone at the start, with no difference between HF or non-HF.

ESC HF 2019 Addition of patiromer to spironolactone showed that a higher percentage of patients remained on spironolactone vs. those on placebo and spironolactone at the start, with no difference between HF or non-HF.

Intensive BP lowering also seems beneficial in adults with diabetes, irrespective of baseline BP

Literature - May 20, 2019 - Rahman F et al. - Hypertension. 2019
An analysis of the ADVANCE study shows that the treatment effect of perindopril-indapamide in patients with diabetes is independent of SBP, DBP or 10-year ASCVD risk at baseline.

An analysis of the ADVANCE study shows that the treatment effect of perindopril-indapamide in patients with diabetes is independent of SBP, DBP or 10-year ASCVD risk at baseline.

Brain aminopeptidase A inhibitor reduces blood pressure in a high-risk diverse population

Literature - May 13, 2019 - Ferdinand KC et al. - Circulation 2019

First-in-class firibastat, a selective and specific inhibitor of brain aminopeptidase A, safely reduced BP in hypertensive, overweight patients of multiple ethnic origins.

Renal denervation associated with SBP reduction in meta-analysis of sham-controlled trials

Literature - Apr. 17, 2019 - Sardar P et al., - J Am Coll Cardiol. 2019

Analysis of data of six randomized sham-controlled trials of renal sympathetic denervation, shows that RSD gave greater reduction in 24-h ambulatory, daytime ambulatory and office SBP and DBP.

Achieving very low BP in patients with diabetes associated with higher CV risk

Literature - Apr. 9, 2019 - Böhm M et al., - Eur Heart J, 2019

ONTARGET and TRANSCEND data show a non-linear association between mean achieved SBP and DBP and clinical outcomes, and event risk was higher in diabetes vs. no diabetes, across the BP spectrum

Less brain damage with intensive BP-lowering in older hypertensives, but no functional improvement

News - Mar. 20, 2019

ACC 2019 The randomized INFINITY trial showed a significant reduction in accrual of subcortical white matter disease in older people receiving more intensive antihypertensive therapy, but mobility and cognitive function were not improved.

Smokers with baseline SBP >144 mmHg may experience harm with intensive BP lowering

Literature - Mar. 12, 2019 - Scarpa J et al. - JAMA Netw Open 2019

An exploratory analysis of SPRINT data using a machine learning method identified a subgroup of smokers with baseline SBP >144 mmHg who had a higher rate of CV events and acute kidney injury with an SBP treatment target of <120 mmHg vs 140 mmHg.

Renal denervation can lower heart rate in unmedicated hypertensive patients

Literature - Mar. 11, 2019 - Böhm M et al., - Eur Heart J. 2019

In the SPYRAL HTN-OFF MED study, RDN lowered HR, particularly in the morning. Patients with HR above the median showed a greater drop in HR and BP than those with lower HR at baseline.

Scientific statement of AHA on measurement of blood pressure

News - Mar. 6, 2019

The AHA has published a scientific statement on correct blood pressure measurement to update findings released in the 2005 version.

Sex differences in trends, treatment and control of CV risk factors in the US from 2001-2016

Literature - Mar. 5, 2019 - Peters SA, et al. - Circulation 2019

A study with representative US citizens showed similar trends for most CV risk factors between men and women from 2001 to 2016, with the exception of BMI and total cholesterol, and sex differences for control of hypertension, diabetes and dyslipidemia.

Bariatric surgery in obese subjects with hypertension results in improved BP outcomes

Literature - Feb. 19, 2019 - Schiavon CA et al. - Hypertension. 2019

Bariatric surgery in obese subjects with hypertension resulted in reduced need for antihypertensive medication with similar ABPM profile and nondipping status, and reduced BP variability and lower number of patients with resistant hypertension compared to medical therapy.